1. Volume 373, Issue 9660, Pages 301-308 (January 2009)
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial 
Anders Widmark, MD, Olbjørn Klepp, MD, Arne Solberg, MD, Jan-Erik Damber, MD, Anders Angelsen, MD, Per Fransson, PhD, Jo- Åsmund Lund, MD, Ilker Tasdemir, MD, Morten Hoyer, MD, Fredrik Wiklund, PhD, Sophie D Fosså, MD 
The Lancet 
Volume 373, Issue 9660, Pages (January 2009)
DOI: /S (08)
Copyright © 2009 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The Lancet  , DOI: ( /S (08) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

3. Figure 2
Cumulative incidence of (A) PSA recurrence, (B) death from prostate cancer, and (C) death from any cause
The Lancet  , DOI: ( /S (08) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

4. Figure 3
Absolute risk reduction in 10-year cumulative incidence of prostate-cancer-specific mortality in the endocrine plus radiotherapy group as compared to the endocrine alone group stratified by T stage, diagnostic PSA level, and age at start of treatment
The Lancet  , DOI: ( /S (08) )
Copyright © 2009 Elsevier Ltd Terms and Conditions